First Patient Enrolled in Landmark CareDx OKRA Registry

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

How To Control a Radio Frequency (RF) Process

The radio frequency welding and manufacturing process uses electromagnetic energy and pressure to fuse and permanently bond vinyl, thermoplastic, and coated materials to produce a specific product - all according to customer requirements. Using this RF sealing process, a distinct, one-piece perpetual bond is formulated that is both solid and resistant to ripping or tearing. But how is this process controlled, and with what specific tools? Read on.

Today CareDx, Inc. announced the enrollment of the first patient in the Outcomes of KidneyCare in Renal Allografts (OKRA) registry from the University of Maryland School of Medicine.

OKRA is a multicenter, prospective, observational registry, designed to measure outcomes of kidney transplant recipients managed with KidneyCare. KidneyCare complements AlloSure to include multimodality testing with the addition of AlloMap Kidney Gene Expression Profiling and prognostic graft assessment using iBox.

“Our team is excited to be the first center to enroll patients. We moved quickly to get OKRA in place at the University of Maryland School of Medicine (UMSOM) so we can begin offering KidneyCare to our transplant patients,” said Dr. Jonathan Bromberg, MD, PhD, Professor of Surgery, Microbiology and Immunology at UMSOM. “The addition of gene expression and graft survival estimates will provide new information to expand our clinical experience,” echoed Dr. Matthew Weir, MD, Director of the Division of Nephrology, and Professor of Medicine at UMSOM.

The patient transplant registry, which will be comprised of 4,000 transplant patients, is statistically powered to determine the utility of KidneyCare and provide real world data on the use of KidneyCare and AlloSure. OKRA targets more than 50 transplant centers and will enroll 1,500 newly transplanted patients, complementing the Kidney Outcomes Allograft Registry (KOAR) with 1,500 patients, matching both arms with 1,000 control patients.

“Data on 4,000 patients provides the ultimate registry to provide clarity on the utility of AlloSure and KidneyCare, and will generate many insights that show promise in improving patient outcomes,” said Sham Dholakia, Senior Vice President of Medical Affairs at CareDx.

 

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.